

# Simple, rapid antiplatelet therapy response assessment



# Antiplatelet therapy. Is it working?

- At least 1 in 3 patients on antiplatelet therapies do not receive the intended physiological effect<sup>1,2,3</sup>
- 40% of patients receiving clopidogrel (Plavix®) may not adequately respond to therapy<sup>4</sup>
- Hyper-response is associated with an increased risk of bleeding<sup>5</sup>
- Individual response to antiplatelet therapies can change over time<sup>6</sup>

Thus, understanding a patient's unique response to antiplatelet medications is essential for effective medical decision-making.

## VerifyNow testing offers antiplatelet therapy guidance in many clinical scenarios

- Interventional procedures for endovascular aneurysm treatment
- Cardiovascular surgery requiring patients to suspend antiplatelet therapy
- Surgery involving patients taking antiplatelet therapy who are at risk for bleeding

## For better patient management

One of the most cited and utilized platelet reactivity testing systems, VerifyNow is an indispensable aid to understanding the complete patient profile. Monitoring patient response to antiplatelet medication optimizes patient outcomes.

### **VerifyNow testing:**

- Offers platelet reactivity results in minutes
- Measures the effect of antiplatelet therapies prior to a procedure or discharge
- Identifies patients at risk for an antiplatelet-related bleeding or thrombotic event
- Identifies therapeutic noncompliance

### **VerifyNow testing may help:<sup>7</sup>**


- Reduce time off antiplatelet therapy and its associated risks
- Reduce the need for standard pre-op platelet orders
- Optimize patient length of stay prior to surgery
- Reduce 30-day readmissions

## Variability in antiplatelet response

Factors contributing to variations in patient response to antiplatelet medication include:<sup>8</sup>

- Concomitant medications
- Genetic differences
- Current health conditions
- Patient noncompliance

\*PRU = P2Y12 Reaction Units



## Challenge


**Patients with inadequate response to antiplatelet medications may be at significantly greater risk of myocardial infarction and stent thrombosis.**

A number of commonly prescribed antiplatelet medications block the P2Y12 platelet-receptor, reducing the risk of major adverse cardiac events (MACE).

<sup>†</sup>Based on patients with Acute Coronary Syndrome not taking a P2Y12 inhibitor.

## VerifyNow PRUtest™

Measures the level of P2Y12 platelet-receptor blockade to help identify patient response to antiplatelet therapy.



## Challenge

**Whether used alone or as part of a dual antiplatelet therapy, not all patients respond to aspirin equally.**

Up to 30% of patients demonstrate lower-than-expected levels of platelet inhibition while on aspirin therapy, putting them at greater risk of heart attack, stroke and other vascular events.<sup>1,2,3</sup> Alternatively, other patients can exhibit a hyper-response, increasing bleeding risk.<sup>2</sup>

## VerifyNow Aspirin Test

Aids in assessing how aspirin inhibits platelets, allowing rapid, informed treatment decisions.



# Specific drug-receptor site activation


## VerifyNow PRU Test

Uses ADP and PGE1 to measure the degree of P2Y12 platelet-receptor blockade, identifying patient response to a P2Y12 inhibitor.

## VerifyNow Aspirin Test

Utilizes an arachidonic acid-initiated reaction to measure platelet response to aspirin.

Commonly prescribed antiplatelet medications, including clopidogrel (Plavix®), prasugrel (Effient®) and ticagrelor (Brilinta®/Brilique), block the platelet P2Y12 receptor.



## VerifyNow testing supports patient care in many areas of the hospital

- Cardiac Care Unit
- Interventional Neuroradiology Suite
- Emergency Department
- Cardiac Catheterization Laboratory
- Laboratory




# Simple integration into any workflow

- Easy to use
- No pipetting or sample preparation
- Sample-to-answer results in a fully contained, single-use test system

## Uses Light Transmission Aggregometry (LTA)-correlated technology

- Requires no sample manipulation, eliminating analytical sample variation
- Patented, accurate and intuitive
- Gold standard technology for pharmaceutical drug development



# Customer testimonials

“Testing with VerifyNow supports ongoing expansion of the frontiers of endovascular aneurysm treatment by helping minimize risk of perioperative complications.”

**Josser E. Delgado, MD**

Neurointerventionalist  
Abbott Northwestern Hospital  
Neuroscience Institute  
Minneapolis, Minnesota

“I test all patients on platelet inhibitors prior to open heart surgery to assess whether or not antiplatelet therapies are having their desired effect.”

**Pierre R. Tibi, MD**

Cardiothoracic Surgeon and Medical Director  
The James Family Heart Center at YRMC  
West Prescott, Arizona

“Having the VerifyNow system allows me to assess the effect of the chosen antiplatelet treatment strategies and make informed decisions.”

**J. Brent Muhlestein, MD**

Interventional Cardiologist  
Intermountain Heart Institute  
Murray, Utah

## References

- Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD. Platelet function monitoring in patients with coronary artery disease. *J Am Coll Cardiol.* 2007;50(19):1822–1834.
- Krasopoulos G, Brister SJ, Beattie SW, Buchanan MR. Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis. *BMJ.* 2008;336(7637):195–198.
- Steinhubl SR, Talley JD, Braden GA, Tcheng JE, Casterella PJ, Moliterno DJ, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU - Assessing Utegra) multicenter study. *Circulation.* 2001;103(21):2572–2578.
- Stone G, Witzembichler B, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC, et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. *Lancet.* 2013;382(9892):614–263.
- Aradi D, Kirtane A, Bonell L, Gurbel PA, Tantry US, Huber K, et al. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. *European Heart Journal.* 2015;36(27):1762–1771.
- Delgado Almandoz JE, Kadkhodayan Y, Crandall BM, Scholz JM, Fease JL, Tubman DE. Variability in initial response to standard clopidogrel therapy, delayed conversion to clopidogrel hyper-response, and associated thromboembolic and hemorrhagic complications in patients undergoing endovascular treatment of unruptured cerebral aneurysms. *Journal of Neuro Interventional Surgery.* 2014;6:767–773.
- Brizzio ME, Shaw RE, Bosticco B, Collins M, Grau JB, Mak AWC, et al. Use of an objective tool to assess platelet inhibition prior to off-pump coronary surgery to reduce blood usage. *J Invasive Cardiol.* 2012;24(2):49–52.
- Serebruany, VL, Steinhubl SR, Berger PT, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. *Journal of the American College of Cardiology.* 2005;45(2):246–251.
- Price MJ, Walder JS, Baker BA, Heiselman DE, Jakubowski JA, Logan DK, et al. Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial. *J Am Coll Cardiol.* 2012;59(25):2338–2343.
- VerifyNow PRUtest [package insert]. San Diego, CA; Accriva Diagnostics.
- VerifyNow Aspirin Test [package insert]. San Diego, CA; Accriva Diagnostics.

## Corporate Headquarters

Plaza de Europa, 21-23  
08908 L'Hospitalet de Llobregat  
Barcelona, Spain  
+34-93-4010101

## Hemostasis and Acute Care Diagnostics

### Headquarters and Technology Center

180 Hartwell Road  
Bedford, MA 01730-2443  
USA  
+1-781-861-0710

## Worldwide Locations

### The Americas

**Brazil**  
São Paulo  
+55-11-46227878

**Canada**  
Richmond Hill, ON  
+1-800-552-2025 x6115

**Colombia**  
Bogotá  
+57-15-221-052

**Mexico**  
Mexico City  
+52-55-5262-1760

**Uruguay**  
Montevideo  
+5982-481-81-33

**USA**  
Bedford, MA  
+1-781-861-0710

### Asia-Pacific

**Australia**  
Sydney  
+61-02-9098-0200

**China**  
Beijing  
+86-10-59756055

Hong Kong  
+852-2792-7773  
Shanghai  
+86-21-66308671

**India**  
New Delhi  
+91-490-29-550

**Japan**  
Tokyo  
+81-3-5419-1301

**Korea**  
Seoul  
+82-1899-9217

**Thailand**  
Bangkok  
+66-271-226-28/9

### Europe

**Austria**  
Vienna  
+43-1-256-58-000

**Belgium**  
Brussels  
+32-2-7252052

**Czech Republic**  
Prague  
+420-246-090-931

**France**  
Paris  
+33-182-30-86-00

**Germany**  
Munich  
+49-89-909070

**Hungary**  
Budapest  
+36-1-882-73-10

**Italy**  
Milan  
+39-02-25221

### Lithuania

Kaunas  
+370-37-313157

**The Netherlands**  
Breda  
+31-76-5480100

**Poland**  
Warsaw  
+48-22-336-18-00

**Portugal**  
Lisbon  
+351-214247312

**Russia**  
Moscow  
+7-499-124-45-59

**Spain**  
Barcelona  
+34-902-20-30-90

**UK**  
Warrington, England  
+44-1925-810141

[werfen.com](http://werfen.com)

For more information, contact your local Werfen sales representative or distributor.

GEM, Premier, GEM Premier ChemSTAT, ChemSTAT, GEMweb, iQM, Hemochron, VerifyNow, Avoximeter and ROTEM are trademarks of Instrumentation Laboratory Company and/or one of its subsidiaries or parent companies and may be registered in the United States Patent and Trademark Office and in other jurisdictions. The Werfen logo is a trademark of Werfen and may be registered in the Patent and Trademark Offices of jurisdictions throughout the world. All other product names, company names, marks, logos and symbols are trademarks of their respective owners.

©2022 Instrumentation Laboratory. All rights reserved.